On March 16, 2010, Unigene Laboratories Inc. entered into an Amended and Restated Financing Agreement, by and among the Company, Victory Park Management, LLC, as administrative agent and collateral agent, and the Lender party there to. The Restated Financing Agreement amends and restates in its entirety and replaces, the Financing Agreement dated as of September 30, 2008, by and among the Company, Victory Park, as administrative agent and collateral agent, and the Lenders party thereto. A closing under the Restated Financing is scheduled to occur on March 17, 2010. In connection therewith, the company and the VPC Parties have executed a Master Reaffirmation and Amendment to Transaction Documents to acknowledge and reaffirm that the transaction documents entered into, and the liens and security interests granted in connection with, the Original Financing Agreement, secure the Obligations (defined therein) of the Company under the Original Financing Agreement, as amended and restated and increased, pursuant to the Restated Financing Agreement. These original transaction documents include, without limitation, the Original Financing Agreement, a pledge and security agreement, related intellectual property security agreements, a deposit account control agreement and a mortgage. Under the terms of the Restated Financing Agreement, at the First Closing, the Company will issue to the Lender, and the Lender will purchase, $33,000,000 aggregate principal amount of three-year, senior secured convertible notes, by way of surrender of the three-year, senior secured non-convertible notes that the Company previously issued and sold to the Lenders pursuant to the Original Financing Agreement, in the aggregate principal amount of approximately $19,360,000, and by way of cash payment of approximately $13,640,000 for the balance. In addition, under certain circumstances, the Company may request that the Lender issue up to an additional $3 million aggregate principal amount of Convertible Notes at one subsequent closing, which shall be no later than the second anniversary of the First Closing.

Unigene Laboratories Inc. expected to Report Q1 2010 Results on May 10, 2010. This event was calculated by Capital IQ (Created on March 16, 2010).

Unigene Laboratories Inc. reported earnings results for the fourth quarter and year ended December 31, 2009. Revenue for the quarter was $2,572,000, compared to $4,854,000 for the same quarter last year. Net loss for the quarter was $810,000, or $0.01 per share, compared to a net loss of $2,337,000, or $0.03 per share for the same quarter last year. For the year, the company reported revenue of $12,791,838, operating loss of $12,379,514, loss before income taxes of $13,446,794 and net loss of $13,379,679 or $0.15 per basic and diluted share against revenue of $19,229,433, operating loss of $4,949,973, loss before income taxes of $7,004,010 and net loss of $6,078,422 or $0.07 per basic and diluted share last year.

Unigene Receives Additional Capital in Debt Restructuring; Begins to Revamp Management Team

Unigene Reports Financial Results for Fourth Quarter and Year-End 2009

Q4 2009 Unigene Laboratories, Inc. Earnings Release - After Market Close

UNIGENE LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and

Unigene to Release Fiscal 2009 Results and Host Conference Call

Unigene to Release Fiscal 2009 Results and Host Conference Call

UNIGENE LABORATORIES INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-

Unigene to Release Third Quarter 2009 Results and Host Conference Call

Unigene Announces Financial Results for Third Quarter 2009

Unigene Announces Promising Preclinical Results in Its Obesity Peptide Program

Independent Advisory Committee Recommends Continuation of Phase III Oral Calcitonin Studies for Osteoporosis and Osteoarthritis

Unigene Announces Significant Cost Savings and Corporate Restructuring

Unigene Files Shelf Registration Statement

Unigene Files Shelf Registration Statement

Unigene Announces Promising Preclinical Results in Its Obesity Peptide Program

UNIGENE LABORATORIES INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Financial Statements

Unigene Announces Significant Cost Savings and Corporate Restructuring

Independent Advisory Committee Recommends Continuation of Phase III Oral Calcitonin Studies for Osteoporosis and Osteoarthritis

Unigene Licenses Phase III Oral Calcitonin Program to Tarsa Therapeutics

U.S. District Court Confirms Validity of Unigene's Fortical® Patent